News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Stressgen Biotechnologies Corporation (SSB.TO) Announces First Quarter 2004 Financial Conference Call

10/19/2005 5:11:03 PM

VICTORIA and SAN DIEGO, CA, April 26 /PRNewswire-FirstCall/ -- Stressgen Biotechnologies Corporation (TSX:SSB) announced today that it will hold a conference call on Thursday, May 6, 2004, at 9:00 a.m. Eastern Time to discuss its first quarter 2004 financial results and provide an update on the progress of the Company.

Stressgen senior management representatives participating in the call will include: Daniel L. Korpolinski, President and CEO; Gregory M. McKee, Vice President of Corporate Development and CFO; Marvin I. Siegel, Ph.D., Executive Vice President of Research and Development; and John R. Neefe, M.D., Senior Vice President of Clinical Development. A question and answer period will follow the Company discussion.

Dial-in numbers and instructions to participate in the conference call ---------------------------------------------------------------------- No passcode required North America (U.S. and Canada) ------------------------------- 1-877-857-2512 International ------------- 1-706-679-5272 Post-view for conference call ----------------------------- Dial: 1-800-642-1687 (U.S. and Canada) 1-706-645-9291 (International) Conference ID: 7021756 Available through May 13, 2004 About Stressgen Biotechnologies Corporation: --------------------------------------------

Stressgen, a biopharmaceutical company, focuses on the discovery, development and commercialization of innovative immunotherapeutics for the treatment of infectious diseases and cancer. In addition to developing HspE7 for diseases caused by HPV, the Company has also initiated research studies to evaluate stress protein fusions made through its CoVal(TM) technology for the treatment of hepatitis B and herpes simplex and is targeting hepatitis C. Stressgen is also an internationally recognized supplier of research products used by scientists worldwide for the study of cellular stress, apoptosis, oxidative stress and neurobiology.

The Company is publicly traded on the TSX Toronto Stock Exchange under the symbol SSB.

About CoVal(TM) Fusion Proteins -------------------------------

Stressgen capitalizes upon the immunostimulatory powers of heat shock proteins utilizing recombinant technology to fuse, or covalently link, a stress protein with a protein antigen to create a single hybrid protein designed to trigger the immune system to recognize that antigen. For more information about CoVal(TM) fusion technology, or Stressgen, please visit the Company at its website located at

This press release contains forward-looking statements regarding the timing of and participants in a planned conference call. Changes in management availability could affect the timing of or speakers in the conference call. See Stressgen's periodic filings with the Securities and Exchange Commission and Canadian regulatory authorities, including its most recent quarterly report, for information about key personnel and other risk factors that could affect Stressgen's performance.

Stressgen Contacts: ------------------- Donna Slade Jennifer Matterson Director, Investor Relations Communications Coordinator 6055 Lusk Boulevard 350-4243 Glanford Avenue San Diego, CA USA 92121 Victoria, BC CANADA V8Z 4B9 Tel: 858/202-4900 Tel: 250/744-2811 Dir: 858/202-4945 Fax: 250/744-3331 Fax: 858/450-6849

StressGen Biotechnologies Corp.

CONTACT: Stressgen Contacts: Donna Slade, Director, Investor Relations,6055 Lusk Boulevard, San Diego, CA, USA, 92121, Tel: (858) 202-4900, Dir:(858) 202-4945, Fax: (858) 450-6849,; JenniferMatterson, Communications Coordinator, 350-4243 Glanford Avenue, Victoria, BC,CANADA, V8Z 4B9, Tel: (250) 744-2811, Fax: (250) 744-3331,

Read at

comments powered by Disqus